Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ganga PharmaceuticalsBOM:539680 67 Debt-to-EBITDA is 1.88 as of Mar. 2026, which is 59% below its 10-year median of 4.61. GuruFocus rates BOM:539680 with a GF Score™ of 67/100 and a GF Value™ of ₹15.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 678 Drug Manufacturers companies, Ganga Pharmaceuticals ranks better than 51.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ganga Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
BOM:539680'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.54 Med: 4.61 Max: 6.51
Current: 1.54
During the past 12 years, the highest Debt-to-EBITDA Ratio of Ganga Pharmaceuticals was 6.51. The lowest was 1.54. And the median was 4.61.
BOM:539680's Debt-to-EBITDA is ranked better than 51.77% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs BOM:539680: 1.54
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ganga Pharmaceuticals Debt-to-EBITDA Related Terms
Ganga Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ganga Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ganga Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ganga Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Mar. 2026) EBITDA data.
Ganga Pharmaceuticals (BOM:539680) has a Debt-to-EBITDA of 1.88 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ganga Pharmaceuticals. This is 59% below median its historical median of 4.61. Over the past decade, Ganga Pharmaceuticals' Debt-to-EBITDA has ranged from 1.54 to 6.51. According to the industry distribution chart, Ganga Pharmaceuticals ranks #327 out of 678 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Ganga Pharmaceuticals' Debt-to-EBITDA too high?
Ganga Pharmaceuticals' current Debt-to-EBITDA of 1.88 is 59% below median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 6.51. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Ganga Pharmaceuticals' value of 1.88 is 14.6% above this industry median. Based on the distribution chart, Ganga Pharmaceuticals ranks #327 out of 678 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ganga Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ganga Pharmaceuticals' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ganga Pharmaceuticals ranks #327 out of 678 companies for Debt-to-EBITDA. This puts Ganga Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Ganga Pharmaceuticals' value of 1.88 is 14.6% above this benchmark. Historically, Ganga Pharmaceuticals' own Debt-to-EBITDA has ranged from 1.54 to 6.51 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 1.64, Ganga Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ganga Pharmaceuticals's current Debt-to-EBITDA of 1.88 is 14.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ganga Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ganga Pharmaceuticals's current Debt-to-EBITDA is 1.88, which is 59% below median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ganga Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ganga Pharmaceuticals (BOM:539680) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹15.51, compared to a current price of ₹12.50 — trading 19.4% below its estimated fair value. The current Debt-to-EBITDA is 1.88, which is 59% below median its 10-year median of 4.61 and 14.6% above the Drug Manufacturers industry median of 1.64. Ganga Pharmaceuticals' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ganga Pharmaceuticals (BOM:539680), the current Debt-to-EBITDA is 1.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ganga Pharmaceuticals (BOM:539680) Overvalued in 2026?
Based on GuruFocus' analysis, Ganga Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹12.50 is trading 19.4% below its estimated GF Value™ of ₹15.51.
GuruFocus considers Ganga Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:539680:
Debt-to-EBITDA: 1.88 (59% below median its 10-year median of 4.61)
GF Value™: ₹15.51 vs. price of ₹12.50 (19.4% below fair value)
Industry Position: 14.6% above the Drug Manufacturers median (#327 of 678)
No single metric tells the full story. See the BOM:539680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.
67GF Score
Get the complete analysis for BOM:539680
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539680 has been successfully added to your 
